---
title: "Why We Need a Decentralized FDA - QuantiModo"
description: "It takes over 10 years and $2.6 billion to bring a drug to market (including failed attempts). It costs $41k per subject in Phase III clinical trials."
ogImage: "https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/62446ff9efd690330920843c_studied-molecules-chart.png"
canonicalUrl: "https://quantimodo.com/blog/why-clinical-research-has-failed"
---
{% include "header.njk" %}

<section class="section blog-post"><div class="container-medium-772px blog-post-content-top"><div data-w-id="0ed8d5c1-70c1-fe92-25b3-122c8197f7a9" style="opacity:0" class="card-post-item-about-wrapper"><div class="card-post-item-about-content"><img src="https://cdn.prod.website-files.com/61f4b7c99c4bc02769eb5cb8/61f4b7c99c4bc06f3aeb5d3b_icon-1-post-about-dark-template.svg" loading="eager" alt="" class="image card-post-item-about-icon"/><div bind="0ed8d5c1-70c1-fe92-25b3-122c8197f7ac">May 16, 2023</div></div><div bind="0ed8d5c1-70c1-fe92-25b3-122c8197f7ad" class="card-post-item-about-content"><img src="https://cdn.prod.website-files.com/61f4b7c99c4bc02769eb5cb8/61f4b7c99c4bc0d18ceb5d3c_icon-2-post-about-dark-template.svg" loading="eager" alt="" class="image card-post-item-about-icon"/><div bind="0ed8d5c1-70c1-fe92-25b3-122c8197f7af">7</div><div> min read</div></div></div><h1 bind="48c22d11-237c-4332-eb9a-eb53aeef8caa" data-w-id="48c22d11-237c-4332-eb9a-eb53aeef8caa" style="-webkit-transform:translate3d(0, 40%, 0) scale3d(0.8, 0.8, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40%, 0) scale3d(0.8, 0.8, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40%, 0) scale3d(0.8, 0.8, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40%, 0) scale3d(0.8, 0.8, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" class="title blog-post">Why We Need a Decentralized FDA</h1><p bind="c38f4ba5-e345-f4ee-e64e-0af1455c0bb9" data-w-id="c38f4ba5-e345-f4ee-e64e-0af1455c0bb9" style="-webkit-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" class="paragraph text-neutral-200 blog-post">It takes over 10 years and $2.6 billion to bring a drug to market (including failed attempts). It costs $41k per subject in Phase III clinical trials.</p><a bind="94eadcaf-edf1-185c-0f35-b0456985ad9d" data-w-id="94eadcaf-edf1-185c-0f35-b0456985ad9d" style="-webkit-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" href="../team/mike-p-sinn.html" class="blog-post-author-link w-inline-block"><div class="image-wrapper blog-post-author"><img alt="" loading="eager" bind="ea80eab9-da0a-b35d-a3fc-76a61d17e2d9" src="https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/65d5860d9dcec77988a9cb7d_mike-kid-slide-smiling-avatar-head.png" class="image blog-post-author"/></div><div class="blog-post-author-content"><div bind="3237acc2-ce7f-d360-9347-ec48dd878173" class="blog-post-author-name">Mike P. Sinn</div><div bind="e945b5b7-b1f3-12c8-323c-8130cf0b29df" class="blog-post-author-rol">Development Lab</div></div></a></div><div class="container-default blog-post w-container"><div data-w-id="0f03f0f2-5df4-1a29-d9db-fb20167b480e" style="-webkit-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" class="image-wrapper blog-post"><img alt="" loading="eager" bind="d58ca6db-552e-811c-e219-5b3a038eb23f" src="https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/62446ff9efd690330920843c_studied-molecules-chart.png" sizes="(max-width: 479px) 93vw, (max-width: 767px) 94vw, (max-width: 1919px) 95vw, 1198px" srcset="https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/62446ff9efd690330920843c_studied-molecules-chart-p-500.png 500w, https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/62446ff9efd690330920843c_studied-molecules-chart.png 648w" class="image blog-post"/></div><div class="bg-gradient-blur-wrapper big blog-post"><div class="bg-gradient-blur-circle-3 pink big"></div><div class="bg-gradient-blur-circle-2 blue-2"></div><div class="bg-gradient-blur-circle-1 purple-2 big"></div></div></div><div class="container-medium-841px blog-post-body"><div bind="b6866799-bb5c-8613-112e-e2b6ecfc7310" data-w-id="b6866799-bb5c-8613-112e-e2b6ecfc7310" style="-webkit-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40px, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" class="rich-text w-richtext"><p>It takes over <a href="https://www.semanticscholar.org/paper/Innovation-in-the-pharmaceutical-industry%3A-New-of-DiMasiGrabowski/3275f31c072ac11c6ca7a5260bd535720f07df41">10 years and $2.6 billion</a> to bring a drug to market (including failed attempts). It costs <a href="https://www.clinicalleader.com/doc/getting-a-handle-on-clinical-trial-costs-0001#:~:text=The%20clinical%20trials%20cost%20a,and%20benchmarking%20clinical%20trial%20costs.">$41k</a> per subject in Phase III clinical trials.</p><p>The high costs lead to:</p><h1><strong>1. No Data on Unpatentable Molecules</strong></h1><p>We still know next to nothing about the long-term effects of 99.9% of the 4 pounds of over <a href="https://www.dailymail.co.uk/health/article-8757191/Are-additives-food-making-ill.html">7,000</a> different synthetic or natural compounds. This is because there&#x27;s only sufficient incentive to research patentable molecules.</p><figure class="w-richtext-align-center w-richtext-figure-type-image"><div><img alt="" src="https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/62446f1ac59fb387ddfd621a_spaces%252FALpB7mDyBf0ce3vSyslF%252Fuploads%252FIv3HH1ej383iABjQORYU%252Fchemicals-in-our-diet.png" loading="lazy"/></div></figure><h1><strong>2. Lack of Incentive to Discover Every Application of Off-Patent Treatments</strong></h1><p>Most of the known diseases (approximately 95%) are classified as rare diseases. Currently, a pharmaceutical company must predict particular conditions to treat before running a clinical trial. Suppose a drug is effective for other diseases after the patent expires. In that case, there isn&#x27;t a financial incentive to get it approved for the different conditions.</p><h1><strong>3. No Long-Term Outcome Data</strong></h1><p>It&#x27;s not financially feasible to collect a participant&#x27;s data for years or decades. Thus, we don&#x27;t know if the long-term effects of a drug are worse than the initial benefits.</p><h1><strong>4. Negative Results Aren&#x27;t Published</strong></h1><p>Pharmaceutical companies tend to only report &quot;positive&quot; results. That leads to other companies wasting money repeating research on the same dead ends.</p><h1><strong>5. Trials Exclude a Vast Majority of The Population</strong></h1><p>One investigation found that only <a href="https://www.ncbi.nlm.nih.gov/pubmed/14628985">14.5%</a> of patients with major depressive disorder fulfilled eligibility requirements for enrollment in an antidepressant trial. Furthermore, most patient sample sizes are very small and sometimes include only 20 people.</p><h1><strong>6. We Only Know 0.000000002% of What is Left to be Researched</strong></h1><p>The more research studies we read, the more we realize we don&#x27;t know. Nearly every study ends with the phrase &quot;more research is needed&quot;.</p><p>If you multiply the <a href="https://www.nature.com/articles/549445a">166 billion</a> molecules with drug-like properties by the <a href="https://www.washingtonpost.com/news/fact-checker/wp/2016/11/17/are-there-really-10000-diseases-and-500-cures/">10,000</a> known diseases, that&#x27;s 1,162,000,000,000,000 combinations. So far, we&#x27;ve studied <a href="https://www.centerwatch.com/articles/12702-new-mit-study-puts-clinical-research-success-rate-at-14-percent">21,000 compounds</a>. That means we only know 0.000000002% of the effects left to be discovered.</p><figure class="w-richtext-align-center w-richtext-figure-type-image"><div><img alt="" src="https://cdn.prod.website-files.com/61f4b7c99c4bc07ab2eb5cc0/62446f1963584f7849567587_spaces%252FALpB7mDyBf0ce3vSyslF%252Fuploads%252FCj4usxr3LWAZVUKVv8eS%252Fstudied-molecules-chart-no-background.png" loading="lazy"/></div></figure><p>‍</p><h2>‍</h2></div>{% include "author-card.njk" %}</div></section>{% include "latest-articles.njk" %}

{% include "footer.njk" %}